SLA e Colesterolo cattivo

LDL alte , utili nella sclerosi amiotrofica laterale

Sanihelp.it -

La sclerosi amiotrofica laterale (ALS) o malattia di Lou Gehrig,

nome attribuito a questa patologia dopo la morte, per sua causa, del famoso giocatore di baseball è un disordine del sistema nervoso centrale che distrugge le cellule responsabili dei movimenti volontari. Ricercatori francesi hanno seguito 369 pazienti affetti da ALS e 286 soggetti sani scoprendo che i malati di ALS mostrano ipercolesterolemia rispetto ai controlli, in particolare i livelli di LDL sono doppi rispetto alla norma.

I malati di ALS con livelli di colesterolo HDL, ovvero quello buono, più alto di quello cattivo LDL, hanno un 35% di possibilità in più di morire:

l’aspettativa media di vita nei soggetti con elevati livelli di LDL è stimata in 49,2 mesi, contro i 36,7 stimati quando i livelli di LDL sono più bassi. Il significato di questa scoperta, purtroppo, non è ancora chiaro, ma già esperimenti precedenti condotti sui topi avevano messo in luce questa stessa strana relazione. -->Tags: ALS LDL HDL Fonte: Reuters Health
di Angela Nanniultima revisione: 11-04-2008

Articoli correlati
- Bassi livelli di colesterolo"buono" sembrano collegati alla demenza- Fibre, queste sconosciute…- Un calendario di esami per tutte le età

2 articoli da PUBmed
Comment in:
Neurology. 2008 Mar 25;70(13):988-9.
Dyslipidemia is a protective factor in amyotrophic lateral sclerosis.
Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, Seilhean D, Hauw JJ, Lacomblez L, Loeffler JP, Meininger V.

Fédération des Maladies du Système Nerveux, Centre référent maladie rare SLA, Hôpital de la Pitié-Salpêtrière, 47-83, Boulevard de l'Hôpital, 75651 Paris, France.

BACKGROUND:

Amyotrophic lateral sclerosis (ALS) is the most serious form of degenerative motor neuron disease in adults, characterized by upper and lower motor neuron degeneration, skeletal muscle atrophy, paralysis, and death. High prevalence of malnutrition and weight loss adversely affect quality of life. Moreover, two thirds of patients develop a hypermetabolism of unknown cause, leading to increased resting energy expenditure. Inasmuch as lipids are the major source of energy for muscles, we determined the status of lipids in a population of patients with ALS and investigated whether lipid contents may have an impact on disease progression and survival.

METHODS:

Blood concentrations of triglycerides, cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) were measured in a cohort of 369 patients with ALS and compared to a control group of 286 healthy subjects. Postmortem histologic examination was performed on liver specimens from 59 other patients with ALS and 16 patients with Parkinson disease (PD).

RESULTS:

The frequency of hyperlipidemia, as revealed by increased plasma levels of total cholesterol or LDL, was twofold higher in patients with ALS than in control subjects. As a result, steatosis of the liver was more pronounced in patients with ALS than in patients with PD. Correlation studies demonstrated that bearing an abnormally elevated LDL/HDL ratio significantly increased survival by more than 12 months.

CONCLUSIONS:

Hyperlipidemia is a significant prognostic factor for survival of patients with amyotrophic lateral sclerosis. This finding highlights the importance of nutritional intervention strategies on disease progression and claims our attention when treating these patients with lipid-lowering drugs.

PMID: 18199832 [PubMed - indexed for MEDLINE]

Neurology. 2008 Mar 25;70(13):1004-9. Epub 2008 Jan 16.
Links
Comment in:
Neurology. 2008 Mar 25;70(13):988-9.
Dyslipidemia is a protective factor in amyotrophic lateral sclerosis.
Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, Seilhean D, Hauw JJ, Lacomblez L, Loeffler JP, Meininger V.

Fédération des Maladies du Système Nerveux, Centre référent maladie rare SLA, Hôpital de la Pitié-Salpêtrière, 47-83, Boulevard de l'Hôpital, 75651 Paris, France.

BACKGROUND:

Amyotrophic lateral sclerosis (ALS) is the most serious form of degenerative motor neuron disease in adults, characterized by upper and lower motor neuron degeneration, skeletal muscle atrophy, paralysis, and death. High prevalence of malnutrition and weight loss adversely affect quality of life. Moreover, two thirds of patients develop a hypermetabolism of unknown cause, leading to increased resting energy expenditure. Inasmuch as lipids are the major source of energy for muscles, we determined the status of lipids in a population of patients with ALS and investigated whether lipid contents may have an impact on disease progression and survival.

METHODS:

Blood concentrations of triglycerides, cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) were measured in a cohort of 369 patients with ALS and compared to a control group of 286 healthy subjects. Postmortem histologic examination was performed on liver specimens from 59 other patients with ALS and 16 patients with Parkinson disease (PD).

RESULTS:

The frequency of hyperlipidemia, as revealed by increased plasma levels of total cholesterol or LDL, was twofold higher in patients with ALS than in control subjects. As a result, steatosis of the liver was more pronounced in patients with ALS than in patients with PD. Correlation studies demonstrated that bearing an abnormally elevated LDL/HDL ratio significantly increased survival by more than 12 months.

CONCLUSIONS:

Hyperlipidemia is a significant prognostic factor for survival of patients with amyotrophic lateral sclerosis. This finding highlights the importance of nutritional intervention strategies on disease progression and claims our attention when treating these patients with lipid-lowering drugs.
PMID: 18199832 [PubMed - indexed for MEDLINE]